BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens ...
San Francisco, California-- (Newsfile Corp. - January 30, 2025) - BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from ...
BioSpace6 天
BioAge Drops Lead Obesity Asset Months After IPO
It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after ...
FierceBiotech6 天
BioAge axes obesity asset over liver toxicity, pivots to preclinical prospects
BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech has jettisoned the molecule and shifted its focus to a preclinical ...
Medscape6 天
Fatty Liver Screening Gaps Emerge in HIV Care Survey
Major barriers in screening for fatty liver disease in patients with HIV included uncertainties about testing, diagnostic ...